Article ; Online: Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients.
Orphanet journal of rare diseases
2023 Volume 18, Issue 1, Page(s) 172
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) results from a mutation in the phosphatidylinositol glycan class-A gene which causes uncontrolled complement activation with resultant intravascular hemolysis and its sequelae. Eculizumab is a terminal complement ...
Abstract | Paroxysmal nocturnal hemoglobinuria (PNH) results from a mutation in the phosphatidylinositol glycan class-A gene which causes uncontrolled complement activation with resultant intravascular hemolysis and its sequelae. Eculizumab is a terminal complement inhibitor that blocks this complement activation and has revolutionized the treatment of PNH but comes with an enormous price which can have catastrophic health expenditure in low-middle income countries (LMIC) like Nepal. Here, we discuss the potential way forwards in the treatment of PNH in Nepal and other LMICs. |
---|---|
MeSH term(s) | Humans ; Hemoglobinuria, Paroxysmal/drug therapy ; Health Expenditures ; Nepal ; Antibodies, Monoclonal, Humanized/therapeutic use |
Chemical Substances | eculizumab (A3ULP0F556) ; Antibodies, Monoclonal, Humanized |
Language | English |
Publishing date | 2023-06-30 |
Publishing country | England |
Document type | Letter |
ZDB-ID | 2225857-7 |
ISSN | 1750-1172 ; 1750-1172 |
ISSN (online) | 1750-1172 |
ISSN | 1750-1172 |
DOI | 10.1186/s13023-023-02779-2 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.